Prices delayed by at least 15 minutes | Print


Accelerate Diagnostics (AXDX)

Common Shares
Sell: $0.89|Buy: $0.905|Change: 0.01 (1.23%)

Open 

$0.889984


Previous close 

$0.8802


Trade high 

$0.93


Volume 

6,235


Year high 

$11.90


Year low 

$0.73


Dividend yield 

-


Market capitalisation 

$19.30 mn


P/E ratio 

-


ISIN 

US00430H2013


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Performance 13/05/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
Accelerate Diagnostics+ 1.23
More...

Company profile

Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.